Role of Prostacyclin and Thromboxane A2 in Ischaemic Heart Disease

  • G. G. Neri Serneri
  • G. F. Gensini
  • G. Masotti
  • R. Abbate
  • A. Morettini
  • L. Poggesi
  • A. Fortini
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 164)


Many investigations have shown that cardiac tissue is able to produce prostaglandins (PGs) of D, E, F series and over all prostacyclin (1–3) both in animals and in humans. Much evidence indicates that the primary site of PGs synthesis is the coronary vasculature and not the cardiac myocytes (3,4).


Platelet Aggregation Ischaemic Heart Disease Adrenergic Stimulation Venous Stasis Coronary Vasospasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    P. Needleman, D.L. Kay, P.C. Isakson, et al., Relationship between oxygen tension, coronary vasodilatation and prostaglandins biosynthesis in the isolated rabbit heart. Prostaglandins 9:123–134 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    K. Schrör, S. Moncada, F.B. Ubatuba, and J.R. Vane, Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. Europ. J. Pharmacol. 47:103–114 (1978).CrossRefGoogle Scholar
  3. 3.
    M. Sivakoff, E. Pure, W. Hsueh, and P. Needleman, Prostaglandins and the heart. Fed. Proc. 38:78–82 (1979).PubMedGoogle Scholar
  4. 4.
    A. Wennmalm, Prostaglandin-mediated inhibition of noradrenaline release: VI. On the intra-cardiac source of prostaglandins released from isolated rabbit hearts. Acta Physiol. Scand. 105:254–256 (1979).PubMedCrossRefGoogle Scholar
  5. 5.
    A.P. Raz, P.C. Isakson, M.S. Minkes, and P. Needleman, Characterization of a novel matabolic pathway of arachidonate in coronary arteries which generates a potent endogenous coronary vasodilator. J. Biol. Chem. 252:1123–1126 (1977).PubMedGoogle Scholar
  6. 6.
    P. Maurer, M.A. Moskowitz, L. Levine, E. Melamed, The synthesis of prostaglandins by bovine cerebral microvessels. Prostagl. Med. 4:153–161 (1980).CrossRefGoogle Scholar
  7. 7.
    N.A. Terragno, and A. Terragno, Prostaglandin metabolism in the fetal and maternal vasculature. Fed. Proc. 38:75–77 (1979).PubMedGoogle Scholar
  8. 8.
    H.H. Davis, W.A. Heaton, B.A. Siegel, C.J. Mathias, J.H. Joist, L.A. Sherman, and M.J. Welch, Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by indium111 -labelled autologous platelets. Lancet i:1185–1187 (1978).CrossRefGoogle Scholar
  9. 9.
    P. Mehta, J. Mehta, C.J. Pepine, et al., Platelet aggregation across the myocardial vascular bed in man: normal versus diseased coronary arteries. Thromb. Res. 14:423–432 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    E.F. Ellis, O. Oelz, L.J. Roberts, et al., Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 193: 1135–1137 (1976).PubMedCrossRefGoogle Scholar
  11. 11.
    M. Hamberg, J. Svensson, and B. Samuelsson, Thromboxanes: a new group of biological active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci.(Wash.) 72: 2994–2998 (1975).CrossRefGoogle Scholar
  12. 12.
    P. Needleman, P.S. Kulkarni, and A. Raz, Coronary tone modulation: formation and actions of prostaglandins, endoperoxides and thromboxanes. Science 195:409–412 (1977).PubMedCrossRefGoogle Scholar
  13. 13.
    Z.I. Terashi, H. Fukui, K. Nishikawa, et al., Coronary vasospastic action of thromboxane A2 in isolated, working guinea pig hearts. Europ. J. Pharmacol. 53:49–56 (1978).CrossRefGoogle Scholar
  14. 14.
    G. Kaley, The role of prostaglandins in vascular homeostasis. Fed. Proc. 35:2358–2359 (1976).PubMedGoogle Scholar
  15. 15.
    P. Neeldeman, and G. Kaley, Cardiac and coronary prostaglandin synthesis and function. N. Engl. J. Med. 298:1122–1128 (1978).CrossRefGoogle Scholar
  16. 16.
    P. Hedqvist, Actions of prostacyclin (PGI2) on adrenergic neuroeffector transmission in the rabbit kidney. Prosta glandins 17:249–258 (1979).Google Scholar
  17. 17.
    A.G. Herman, T.J. Verbeuren, S. Moncada, and P.M. Van Houtte, Effects of prostacyclin on myogenic activity and adrenergic neurofactor interaction in canine isolated veins. Prostaglandins 16:911–921 (1978).PubMedCrossRefGoogle Scholar
  18. 18.
    G.G. Neri Serneri, E. Silvestrini, P. Paoletti, and G. Masotti, Studi sulle sindromi trombofiliche. V. L’adesivita e 1’aggregazione delle piastrine nella malattia ateromasica. Riv. Clin. Med. 68, (suppl. 6), 47 (1978).Google Scholar
  19. 19.
    A. Szczeklik, R.J. Gryglewski, J. Musial, L. Grodzinska, M. Serwonska, and E. Marcinkiewicz, Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb. Haem. 40:66 (1978).Google Scholar
  20. 20.
    P. Mehta, J. Mehta, C.J. Pepine, T.D. Miale, and C. Burger, Platelet aggregation across the myocardial vascular bed in man: normal versus diseased coronary arteries. Thromb. Res. 14:423 (1979).PubMedCrossRefGoogle Scholar
  21. 21.
    H.H. Davis, B.A. Siegel, J.H. Joist, W.A. Heaton, C.J. Mathias, L.A. Sherman, and M.J. Welch, Scintigraphic detection of atherosclerotic lesions and venous thrombi in mann by indiunv-111 -labelled autologous platelets. Lancet i:1185 (1978).CrossRefGoogle Scholar
  22. 22.
    M.K. Dewanjee, V. Puster, M. P. Kaye, and M. Josa, Imaging platelet deposition with 111-In-labelled platelets in coronary artery by pass grafts in dogs. Mayo. Clin. Proc. 53:327 (1978).PubMedGoogle Scholar
  23. 23.
    S. Moncada, E.A. Higgs, and J.R. Vane, Human arterial and venous tissue generate prostacyclin (Prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1:18 (1977).PubMedCrossRefGoogle Scholar
  24. 24.
    S. Moncada, R. Gryglewski, S. Bunting, and J.R. Vane, An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:633 (1976).CrossRefGoogle Scholar
  25. 25.
    P. Needleman, S.D. Bronson, A. Wyche, M. Sivakoff, and K.G. Nicolau, Cardiac and renal prostaglandin I2 — Biosynthesis and biological effects in isolated perfused rabbit tissues. J. Clin. Invest. 61:839 (1978).PubMedCrossRefGoogle Scholar
  26. 26.
    G.G. Neri Serneri, G. Masotti, L. Poggesi, and G. Galanti, Release of prostacyclin into the blood stream and its exhaustion in humans after local blood changes (ischemia and venous stasis). Thromb. Res. 17:197 (1980).CrossRefGoogle Scholar
  27. 27.
    E. Granström, H. Kindahl, and B. Samuelsson, Radioimmunoassay for thromboxane B2. Analyt. Lett. 9:611 (1976).CrossRefGoogle Scholar
  28. 28.
    R.R. Gorman, S.S. Bunting, and O.V. Miller, Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13:377 (1977).PubMedCrossRefGoogle Scholar
  29. 29.
    E.W. Salzman, Platelets, prostaglandins and cyclic nucleotides. In: Platelets: a multidisciplinary approach. 1st ed., p.227, Editors: G. De Gaetano and S. Garattini, Raven Press, New York, (1978).Google Scholar
  30. 30.
    J.G. White, and J.M. Gerrard, Platelet morphology and the ultrastructure of regulatory mechanisms involved in platelet activation. In: Platelets: a multidisciplinary approach. 1st ed. p. 17, Editors: G. De Gaetano and S. Garattini, Raven Press, New York, (1978).Google Scholar
  31. 31.
    M. Minkes, N. Stanford, M.M.Y. Chi, A.R. Roth, P. Needleman, and P.W. Majerus, Cyclic adenosine 3′, 5′-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. J. Clin. Invest. 59:449 (1977).PubMedCrossRefGoogle Scholar
  32. 32.
    O.V.V. Miller, and R.R. Gorman, Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandins endo-peroxide PGG2. J. Clin. Nucl. Res. 2:7 (1976).Google Scholar
  33. 33.
    O.V. Miller, R.A. Johnson, and R.R. Gorman, Inhibition of PGE1-stimulated cAMP accumulation in human platelets by thromboxane A2. Prostaglandins 13:599 (1977).PubMedCrossRefGoogle Scholar
  34. 34.
    R. Korbut, and S. Moncada, Prostacyclin and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb. Res. 13:489 (1978).PubMedCrossRefGoogle Scholar
  35. 35.
    L.C. Best, T.G. Martin, R.G.G. Russel, and F.E. Preston, Prostacyclin increase cyclic AMP levels and adenylate cyclase activity in platelets. Nature 267:850 (1977).PubMedCrossRefGoogle Scholar
  36. 36.
    G.N. Brodie, N.L. Baenziger, L.R. Chase, and P.W. Majerus, The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets. J. Clin. Invest. 51:81 (1972).PubMedCrossRefGoogle Scholar
  37. 37.
    S. Niewiarowski, and M. Millman, Potentiation of the thrombin induced platelet release reaction by fibrin. Thromb Res. 9:181 (1976).PubMedCrossRefGoogle Scholar
  38. 38.
    G.G. Neri Serneri, R. Abbate, G.F. Gensini, C. Mugnaini, and A. Lagi, Occurrence of a plasmatic platelet aggregating activity in some patients with increased platelet aggregation, In: Advances in Coagulation, Fibrinolysis, Platelet Aggregation and Atherosclerosis, 1st ed., p. 396, Editor A. Strano, C.E.P.I. Roma (1976).Google Scholar
  39. 39.
    G.G. Neri Serneri, R. Abbate, C. Mugnaini, and G.F. Gensini, Increased platelet aggregation due to a plasma aggregating activity. Identification of the responsible factors. Haemostasis 8 (in press) (1979).Google Scholar
  40. 40.
    V. Hofmann, and P.W. Straub, A radioimmunoassay technique for the rapid measurement of human fibrinopeptide A. Thromb. Res. 11:71 (1977).Google Scholar
  41. 41.
    G.G. Neri Serneri, R. Abbate, G.F. Gensini, L. Poggesi, G. Masotti, S. Favilla, C. Mugnaini, and G. Galanti, Prostacyclin and thromboxane release in plasma after adrenergic stimulation. In: Myocardial Infarction, edited by D.T. Mason, G.G. Neri Serneri, M.F. Oliver, pp. 383–387, Excerpta Medica, Amsterdam (1979).Google Scholar
  42. 42.
    G.G. Neri Serneri, G. Masotti, L. Poggesi, R. Abbate, and M. Mannelli, Prostacyclin and thromboxane A2 formation in response to adrenergic stimulation in humans. A mechanism for local control of vascular response to sympathetic activation? Card. Res.(In press) (1981).Google Scholar
  43. 43.
    G.G. Neri Serneri, G. Masotti, L. Poggesi, G. Galanti, A. Morettini, and L. Scarti, Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am. J. Cardiol. (In press) (1981).Google Scholar
  44. 44.
    M.J. Armstrong, G. Thirsk, and J.A. Salmon, Effects of prostacyclin (PGI2), 6-oxo-PGF and PGE2 on sympathetic nerve function in mesenteric arteries and veins of the rabbit in vitro. Hypertension 1:309–315 (1979).PubMedCrossRefGoogle Scholar
  45. 45.
    H. Jasue, S. Tanaka, and F. Akiyama, Prinzmetal’s variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm: documantation by coronary arteriography. Am. Heart J. 91:148–155 (1976).CrossRefGoogle Scholar
  46. 46.
    D.L. Levene, and M.R. Friedman, Alpha-adrenoceptor-mediated coronary artery spasms. JAMA 236:1018–1022 (1976).PubMedCrossRefGoogle Scholar
  47. 47.
    D.R. Ricci, A.E. Orlick, P.R. Cipriano, D.F. Guthaner, and D.C. Harrison, Altered adrenergic activity in coronary arterial spasm. Insight into a mechanism based on study of coronary hemodynamics and the electrocardiogram. Am. J. Cardiol. 43:1073–1079 (1979).PubMedCrossRefGoogle Scholar
  48. 48.
    J.D. Folts, E.B. Crowell, and G.G. Rowe, Platelet aggregation in partially obstructed vessels and its elimination by aspirin. Circulation 54:365 (1976).PubMedCrossRefGoogle Scholar
  49. 49.
    L.D. Hills, and E. Braunwald, Coronary-artery spasm. N. Engl. J. Med. 299, 695 (1978).CrossRefGoogle Scholar
  50. 50.
    G.H. Mudge, R.H. Grossman, R.H. Jr. Mills, M. Lesch, and E. Braunwald, Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N. Engl. J. Med. 295:1333 (1976).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • G. G. Neri Serneri
    • 1
  • G. F. Gensini
    • 1
  • G. Masotti
    • 1
  • R. Abbate
    • 1
  • A. Morettini
    • 1
  • L. Poggesi
    • 1
  • A. Fortini
    • 1
  1. 1.Istituto di Clinica Medica IVUniversity of FlorenceFlorenceItaly

Personalised recommendations